Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% reduction in the placebo group.

NCT05564117), a 64-week study that included a 12-week dose escalation and a 7-week off-treatment follow-up period. Study participants were randomly assigned 2:1 to receive oral semaglutide 25mg (n ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

The risk for ocular problems linked to different formulations of semaglutide appear to vary, according to a new study, which ...

The prospect of a pill rather than an injection is obviously appealing to some people, but will fear of needles be enough to shift the market?

This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

With more and more people signing up for weight loss drugs, the potential side effects are starting to attract attention.

"We are entering a new era of obesity care where patients want individualized treatment plans that address their needs and provide choices, including oral formulations," said Anna Windle ...

Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...